SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma

This is a phase II clinical trial testing whether a combination of stereotactic ablative radiotherapy (SABR), axitinib, and toripalimab is effective and safe for treating oligometastatic clear cell renal cell carcinoma (a type of kidney cancer that has spread to 5 or fewer sites). In this study, all metastatic tumors will be treated with SABR - a precise, high-dose radiation therapy delivered in 5 sessions. At the same time, participants will receive axitinib (an oral targeted cancer drug) twice daily, and toripalimab (an intravenous immunotherapy) every 3 weeks for up to 2 years. The study

Trial Details

NCT ID
NCT07744932
Phase
PHASE2
Sponsor
Hebei Medical University Fourth Hospital
Status
RECRUITING
Cancer Type
Clear Cell Renal Cell Carcinoma Kidney Cancer
Interventions
  • axitinib plus toripalimab
  • SABR
Locations (sample)
  • Shijiazhuang, Hebei, China|38.04139,114.47861

Key Eligibility Criteria

  • Histologically confirmed diagnosis of clear cell renal cell carcinoma (ccRCC).
  • Age ≥ 18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  • Radiological evidence of distant metastasis meeting the MD Anderson (MDA) definition of oligometastatic disease: ≤5 metastatic lesions, all amenabl…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Clear Cell Renal Cell Carcinoma Kidney Cancer Trials on Trialify →